Employees: 1,719
Size Shandong Wit Dyne Health (000915.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $687M, the 2932nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.55 on 18 Nov 2026.
Performance Over six months the shares fell 31.1%, against -7.8% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 35.8% over the last twelve months (peer median +4.4%); the operating margin is 36.2% (peer median 9.7%).
Valuation It trades at 9.1× forward earnings against a peer median of 17.0× (2nd cheapest of 11).
Capital Return on invested capital runs 10.0 points above its cost of capital (6.2% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.51B | CN¥2.20B | CN¥2.10B | CN¥2.45B | CN¥2.31B |
| Revenue growth | — | +5% | -15% | +6% | — |
| Gross profit | CN¥1.26B | CN¥1.83B | CN¥1.71B | CN¥2.08B | CN¥1.79B |
| EBITDA | n/a | CN¥1.24B | CN¥1.18B | CN¥1.34B | CN¥1.21B |
| Net income | CN¥284M | CN¥535M | CN¥516M | CN¥585M | CN¥527M |
| Free cash flow | -CN¥7.73M | CN¥1.25B | CN¥915M | CN¥1.15B | CN¥1.13B |
| Capital expenditure | CN¥15.7M | CN¥48.3M | CN¥43.6M | CN¥50.6M | CN¥89.7M |
| Total debt | CN¥0 | CN¥356,348 | CN¥2.86M | CN¥66,955 | CN¥9.89M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000915.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.4% | -2.8% | 2nd lowest of 21 |
| 6-month return | -31.1% | -7.8% | 5th lowest of 21 |
| Distance from 52-week high | -45.9% | -31.1% | 8th lowest of 21 |
| Revenue growth (TTM) | -35.8% | +4.4% | lowest of 18 |
| Operating margin | 36.2% | 9.7% | 3rd highest of 18 |
| Forward P/E | 9.1× | 17.0× | 2nd cheapest of 11 |
| ROIC minus cost of capital | +10.0 pp | +0.0 pp | 3rd highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 10.1× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 112.1× | 31.9% | +19.8% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | n/a | 25.2% | +10.3% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 47.6× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | n/a | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 11.2× | 5.9% | +11.3% |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 32.2× | 27.1% | +31.4% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 7.1× | -11.8% | +1.9% |